Spero Therapeutics (SPRO) News
NASDAQ: SPROHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SPRO news summary
We found 6 recent headlines mentioning Spero Therapeutics (SPRO): 0 in the past week and 5 in the past 30 days, most often from GlobeNewswire, Nasdaq. SPRO is making an outsized move today, down 10.20% at $0.742, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", was published by GlobeNewswire on Nov 4, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Spero Therapeutics headlines
- Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in…GlobeNewswire
- Spero Therapeutics to Present at Investor Conferences in NovemberCAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in…GlobeNewswire
- Cantor Fitzgerald Initiates Coverage of Spero Therapeutics at OverweightFintel reports that on October 28, 2026, Cantor Fitzgerald initiated coverage of Spero Therapeutics (NASDAQGS:SPRO) (DB:2HA) with a Overweight recommendation.Spero Therapeutics, Inc., based in the…Nasdaq
- Spero Therapeutics, Inc. Announces Retirement of Chief Operating Officer Timothy KeutzerSpero Therapeutics, Inc. announced that Timothy Keutzer, the Company’s Chief Operating Officer, will retire from the Company effective as of December 31, 2026.In connection with his retirement,…NasdaqSPRO, DDS
- Spero Therapeutics Strengthens Leadership Team to Advance Immunology PipelineCAMBRIDGE, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients…GlobeNewswire
- Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare ConferenceCAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology…GlobeNewswire